hVIVO #HVO – Result of Secondary Placing February 14, 2024 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has been informed by the Selling Shareholders that, further to the announcement made at 7 a.m. today (the “ABB Announcement”), they have successfully sold a total of 29,955,178 Placing Shares at a price of 28 pence per Placing Share. The Placing Shares in aggregate represent approximately 4.40 per cent. of the…

hVIVO #HVO – JP Morgan significant shareholding February 2, 2024 – Posted in: Blog, hVIVO (HVO)

TRI: JP Morgan Asset Management UK Ltd have acquired 21,878,759 shares (3.215703%) indirect voting rights and 12,446,678 shares (1.829392%) and as a result hold a combined 34,325,437 shares (5.045095%) of the company

#HVO hVIVO PLC – Interim results September 12, 2023 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its unaudited interim results for the six-month period ended 30 June 2023. Financial highlights · First half revenue growth of 52% to £27.3 million* (H1 2022: £18.0 million) · EBITDA more than doubled to £5.2 million (H1 2022: £2.3 million) · EBITDA margin increased to 19.1% (H1 2022: 12.6%) · Net cash…

hVIVO #HVO raises £90,000 in warrant exercise September 1, 2023 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO) has received notice of exercise of warrants by a former nomad and corporate finance advisor (awarded as part of the IPO of the Company in June 2019), over 1,607,142 ordinary shares of 0.1 pence each in the capital of the Company (“Ordinary Shares”) at a price of 5.6 pence per share. The gross proceeds of this exercise received by the Company amount to £90,000. The total remaining outstanding warrants over Ordinary Shares are as follows: Number…

#HVO hVIVO – Notice of Results August 24, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will release its interim results for the six months ended 30 June 2023 on Tuesday 12 September 2023. Investor presentation Yamin ‘Mo’ Khan, Chief Executive Officer, and Stephen Pinkerton, Chief Financial Officer, will provide a live presentation relating to the interim results via the Investor Meet Company platform on…

hVIVO PLC #HVO – Director dealings June 14, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) announces that it has received notification that Yamin ‘Mo’ Khan, Chief Executive Officer of the Company, yesterday acquired 13,526 ordinary shares of 0.1 pence each in the capital of the Company as a result of a dividend reinvestment plan. Following the purchase of shares Mo holds 523,730 ordinary shares representing approximately 0.08 per cent of the Company’s issued ordinary capital. For further information please contact:…

#HVO hVIVO PLC – Annual Report and Notice of AGM April 28, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, confirms that the Company’s Annual Report and Accounts for the year ended 31 December 2022 and the Notice of Annual General Meeting (“AGM”) will be posted to shareholders today. The 2022 Annual Report and Accounts, the Notice of AGM and accompanying form…

#HVO hVIVO PLC – Presentation at World Vaccine Congress March 29, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that Dr Andrew Catchpole, Chief Scientific Officer, will be delivering a presentation at the World Vaccine Congress, Washington D.C., United States. Full details of the presentation are included below: Title Challenge Studies – can the results be expected to mimic…

Markets and Stocks January 2023 – Doc Holliday talks to Alan Green January 19, 2023 – Posted in: Blog, hVIVO (HVO), Poolbeg Pharma (POLB)

Markets and Stocks January 2023 – Doc Holliday talks to Alan Green. We look at Doc’s new Twitter Spaces cast, before turning to stocks: 04:00 Avacta #AVCT | 06:00 Hvivo #HVO & Poolbeg Pharma #POLB | 08:15 – Longboat Energy #LBE / Energy stocks | 11:26 – Cadence Minerals #KDNC | 14:55 – Mining Companies | 17:40 – Argo Blockchain #ARB | 21:20 – Revolution Bars #RGB | 26:26 – Over the next few months |…

#HVO hVIVO PLC – £5.2m RSV contract and Notice of Trading update January 4, 2023 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed a £5.2m contract with a global biotechnology company headquartered in Asia Pacific to test their respiratory syncytial virus (“RSV”) vaccine candidate, using hVIVO’s established RSV Human Challenge Study Model. The Company also announces that it will provide…